Gene Biotherapeutics Inc CRXM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.05
- Market Cap
- $64.93
- Volume/Avg
- 312 / 305
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
Valuation
|
Metric
|
CRXM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRXM
|
|---|---|
Quick Ratio | 0.08 |
Current Ratio | 0.08 |
Interest Coverage | −10.35 |
Quick Ratio
CRXM
Profitability
|
Metric
|
CRXM
|
|---|---|
Return on Assets (Normalized) | −216.41% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CRXM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fzpcyxlwj | Jhjx | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lvrjkrk | Cvnqh | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fznnlbbp | Hmzxrrd | $105.9 Bil | |
MRNA
| Moderna Inc | Nqbhldmf | Bvzx | $46.4 Bil | |
ARGX
| argenx SE ADR | Mswtdrvj | Sgt | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Wdnkdgmp | Hkkh | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lcjmjltk | Ntrxdr | $19.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wxtwtjqv | Rdrtyf | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zllpyywxwn | Kbmskqn | $12.8 Bil | |
INCY
| Incyte Corp | Glrdhfcf | Dycws | $12.2 Bil |